Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sonoma Pharmaceuticals (SNOA) Debt to Equity (2016 - 2025)

Sonoma Pharmaceuticals has reported Debt to Equity over the past 15 years, most recently at $0.01 for Q3 2025.

  • For Q3 2025, Debt to Equity fell 3.48% year-over-year to $0.01; the TTM value through Sep 2025 reached $0.01, down 3.48%, while the annual FY2025 figure was $0.05, 5.24% down from the prior year.
  • Debt to Equity for Q3 2025 was $0.01 at Sonoma Pharmaceuticals, down from $0.03 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.36 in Q1 2021 and troughed at $0.0 in Q4 2022.
  • A 5-year average of $0.06 and a median of $0.04 in 2024 define the central range for Debt to Equity.
  • On a YoY basis, Debt to Equity climbed as much as 315.54% in 2021 and fell as far as 85.23% in 2021.
  • Year by year, Debt to Equity stood at $0.02 in 2021, then crashed by 84.46% to $0.0 in 2022, then surged by 143.67% to $0.01 in 2023, then skyrocketed by 133.02% to $0.02 in 2024, then decreased by 3.48% to $0.01 in 2025.
  • Business Quant data shows Debt to Equity for SNOA at $0.01 in Q3 2025, $0.03 in Q2 2025, and $0.05 in Q1 2025.